NovaBridge Biosciences/$NBP
1D1W1MYTD1Y5YMAX
Capital at risk
About NovaBridge Biosciences
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
- Ticker
- $NBP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Rockville, United States
- Website
- novabridge.com
NBP Metrics
BasicAdvanced
$157M
-
-$1.04
1.48
-
Price and volume
Market cap
$157M
Beta
1.48
52-week high
$6.79
52-week low
$1.31
Average daily volume
508K
Financial strength
Current ratio
7.638
Quick ratio
7.58
Long term debt to equity
0.016
Total debt to equity
0.022
Profitability
EBITDA (TTM)
-122.527
Management effectiveness
Return on assets (TTM)
-34.98%
Return on equity (TTM)
-59.10%
Valuation
Price to book
0.78
Price to tangible book (TTM)
0.78
Price to free cash flow (TTM)
-3.275
Free cash flow yield (TTM)
-30.54%
Free cash flow per share (TTM)
-0.414
Growth
Earnings per share change (TTM)
112.59%
3-year earnings per share growth (CAGR)
-34.98%
What the Analysts think about NBP
Analyst ratings (Buy, Hold, Sell) for NovaBridge Biosciences stock.
Analyst projections of the future price of NovaBridge Biosciences stock.
NBP Financial Performance
Revenues and expenses
NBP Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing NBP
AllUSDGBP
Fund name | Fund size | $NBP weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.01% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.